Ibrutinib generally improves anemia and gives prolonged disease control (1) while ruxolitinib caused significant anemia, potentially from increases in TNFα that can suppress erythropoiesis (17), and had little therapeutic activity during the time it was administered to patients (13). This evidence concerns the gene TNF and anemia (phenotype).